$MU: Nvidia's Jensen Huang says memory supply is unlikely to outstrip demand by 2029. That one line is the Micron thesis. Micron backs it up. Its entire 2026 HBM supply, including HBM4, is sold out, and CEO Sanjay Mehrotra expects supply to stay tighter than demand through 2027 and 2028. Pricing is following the shortage. J.P. Morgan just raised its fourth-quarter DRAM contract price forecast to a 10% to 15% increase, up from 3% to 8%. NAND: 15% to 20%, up from flat to 5%. When customers sign long-term supply deals, they are telling you what they expect. Nobody locks in supply that far out ahead of a glut. The stock is still trading like the cycle could turn tomorrow. Micron's own outlook says otherwise, at least through 2028. TradeSmith's Quantum Score fundamental read on Micron: 94 out of 100. Is the 2029 call too bullish, or not bullish enough?

12 oil and gas stocks hit new one-year highs on Friday, led by Exxon Mobil $XOM and Chevron $CVX. The full list at one-year highs: $XOM, $CVX, $EOG, $COP, $APA, $SU, $CNQ, $PBR, $BP, $SHEL, $E and $EQNR. That's U.S. majors and producers, Canadian producers, Brazil's Petrobras and the big European integrateds, all moving together. When an entire group breaks out at once, the trend is broad. This is not a one-stock story. Also at a one-year high: American Tower $AMT, the wireless infrastructure and data center REIT. It's another reminder that the data center buildout reaches well beyond the chipmakers. On the other side of the ledger, four names hit new one-year lows. Chipotle $CMG, the fast food giant. Stellantis $STLA, maker of Jeep, Ram and Chrysler. Kratos Defense $KTOS, the military drone and communications leader. A notable reversal for a stock that rose 532% over a recent two-year run. Energy Fuels $UUUU, the uranium mining and rare earth name. The split is clear. Strength in energy and infrastructure, weakness in restaurants, autos and a couple of recent high-flyers. Bookmark this for your watchlist.

The $269 Billion Bill Behind Anthropic's Perfect S-1... Here's the Bull and Bear of it. $269.4 billion. That is how much Anthropic $ANT has promised to pay Google $GOOG, Amazon $AMZN, and Microsoft $MSFT for compute, "regardless of actual usage." Those are the filing's words, not mine. Everyone will lead with the revenue today. They should. It is the best growth chart ever filed with the SEC. $41 million in 2023. $386 million in 2024. $4.6 billion in 2025. Then $16.3 billion in just the first half of 2026, up 1,300% from a year earlier. Net Revenue Retention is roughly 900%. That means a typical group of customers is spending about nine times what it spent a year ago. Read that again. Gross margin was negative in 2024. In the first half of 2026 it was about 85%. Operating cash flow went from negative $1.5 billion to positive $3.9 billion. The company is sitting on $112.4 billion of cash. Even the scary headline number is mostly noise. The $80.7 billion net loss includes $72.4 billion of non-cash charges from marking up its convertible notes and similar instruments. The better Anthropic does, the bigger that "loss" gets. The operating loss was only $693 million. So where is the risk? Here is the setup. 80% of Anthropic's revenue is consumption-based. Customers pay for what they use, when they use it. If usage slows, revenue slows the same month. The costs do not work that way. Google: at least $114.5 billion through July 2033. Amazon: at least $110 billion through April 2036. Microsoft: at least $44.9 billion through May 2033. If Anthropic uses less than it committed to, it pays the difference anyway. The filing calls that a "true-up." Add one more line. Once all capacity is delivered, which Anthropic expects in December, its SpaceXAI compute deal runs about $3.1 billion a month. That is roughly $37 billion a year from one supplier. Anthropic's first-half revenue, doubled, is $32.6 billion. Sit with that number. Revenue can change month to month. The bills are locked in for up to ten years. Anthropic says so plainly. It may "enter into these obligations based on revenue expectations that may not be realized." That reframes the whole document. This is not really a software IPO. It is a giant bet on how fast enterprise AI keeps growing, wrapped around one of the most profitable growth engines ever built. The bull case is simple. Compute is the scarcest input in AI, and Anthropic locked up a decade of it early. Revenue grew 1,368% last quarter while compute costs grew 300%. If that gap holds, these contracts become the best trade of the decade. The bear case is also simple. Usage only has to flatten for a few quarters. Customers can turn the meter down. Google and Amazon still get paid. Both are true at the same time. That is the trade. One more detail. The public gets one vote per share. A single Class F share, held by the seven co-founders, carries 50.1% of the voting power. You get the upside and the risk. They keep control. When the amended filing lands, I am watching three numbers. Q3 revenue, which this version leaves blank. The total compute commitment, also blank. And how much of it is due in the next twelve months. Those three numbers will tell you whether $269.4 billion is a moat or an anchor.

2.37 million people just viewed Chamath calling neoclouds "disorganized and poorly capitalized." $CRWV $NBIS $IREN $CIFR $WULF $HUT $CORZ $APLD $GLXY $ORCL $MSFT Then Elon Musk said debt markets have "almost entirely shut off" for companies without substantial revenue outside AI data centers. His prediction: "guppy-level death" among 200+ neoclouds. Overnight, $NBIS and $CRWV fell 4%. $IREN and $CIFR fell 3%. The bear case is about funding, not demand. These companies borrow against GPUs that lose value every chip cycle, and the Nebius CEO says the bond market just closed to GPU asset-backed debt. The bull case runs through Microsoft $MSFT. It made up 62% of CoreWeave's 2024 revenue, signed a $17.4 billion deal with Nebius and a $9.7 billion deal with IREN. Those contracts are the collateral lenders care about. Oracle $ORCL is the warning label. It is the one big cloud funding its AI buildout mostly with debt, over $100 billion so far, and loans tied to one of its data centers recently traded at 89 to 91 cents on the dollar. So both sides can be right. Neoclouds with long hyperscaler contracts and energized power can still raise money. The ones without are the guppies. And you have to wonder, are they just acquisition targets fueling the online negative chatter? Driving their value way down to acquire them - we see that all the time. What happens next is consolidation, not collapse. Big Tech plans more than $7 trillion of data center and AI spending through 2030, and someone still has to deliver that power. Neoclouds are needed, 100%. The question this week is which balance sheets survive the shakeout. What is your view on Neoclouds?

$XBI is up 68% and $IBB is up 51% since I shared my bullish sentiment on biotech in August of last year. Over the past 10 days, Amgen $AMGN, Biogen $BIIB and Gilead Sciences $GILD all hit new one-year highs. Those leaders have pushed the iShares Nasdaq Biotechnology ETF $IBB to a 36% return over the past year. Yet almost nobody is talking about it. CNBC isn't running long biotech segments. Biotech CEOs aren't on the podcast circuit the way Jensen Huang is. Bring up biotech at an investment conference and you get blank stares. That indifference is the bullish part. A strong industry uptrend plus public indifference is one of the most reliable setups in markets. Trends tend to persist, and ignored markets rarely get bid up to expensive levels. That leaves plenty of valuation room to run, and plenty of sidelined money that could still pile in. TradeSmith's Quantum Score backs up the momentum. $AMGN and $BIIB both carry a Technical Score of 91. The bigger story is AI meeting biology. Researchers running millions of digital simulations can find drug candidates and predict how treatments behave far faster than before. Breakthroughs that once took decades could arrive in years. The last biotech bull market ran 300% over four years. Biotech tends to get a bad rap, how do you feel about it?

Profit is an opinion. Cash is a fact. The income statement can show earnings the company has not collected yet, or smooth costs across years. The cash flow statement tracks the actual dollars that came in and went out. It is much harder to dress up. When profits look great but cash keeps draining, believe the cash. It is the statement that catches the stories the other two can tell.

$IREN closed Friday at $24.91, 67.6% below its 52-week high of $76.87. The contract book is not the problem. The company holds a roughly $9.7 billion, five-year Microsoft deal for 200 MW at Childress, Texas, backed by a $3.65 billion debt package rated A. Last week it secured a license for a roughly 300 MW AI campus in Badajoz, Spain, targeted for 2028. The debate is the balance sheet. At June 30 it held $5.9 billion of cash against $7.59 billion of debt, with a $25 billion to $30 billion capex plan for fiscal 2027. That is the whole neocloud trade in one stock: contracted demand on one side, funding risk on the other. Right now the stock is pricing the second. Wall Street's median target sits near $80. Earnings land Nov 5, one week after the hyperscalers tell us how much they plan to keep spending. Is $IREN a deep-value setup or a balance sheet you avoid?

$SPCX and $TSLA together would be worth about $3.5 trillion. Both boards now have special committees of independent directors studying a combination. Musk's own words: "Do I think it would be a good idea? Yes." He also said calling it a certainty "would be overstating it." The hurdle is real. A deal needs a majority of all outstanding Tesla shares, not just the votes cast. Musk called that "quite a high hurdle." Barclays thinks an announcement could come before Tesla's Dec 3 annual meeting. Meanwhile, supply keeps arriving. Up to 328.4 million more SpaceX shares become tradable Monday. The track record on unlock days is mixed: down 4% in August, flat in September, up 1% on Oct 9, and down nearly 9% on Thursday's 1.3 billion share unlock. The business underneath keeps delivering. Q3 revenue came in at $14.58 billion against a $12.54 billion estimate. SpaceX closed Friday at $147.49, up 1.9%. Would you rather own the rocket company alone or the combined giant?

Apple $AAPL climbed 1.2% to a new all-time high Thursday, while $META fell 7% and $SMH dropped 6%. Memory leader Micron $MU dropped 6%. The Nasdaq Composite had its worst day since June. The market is sending a message. Apple may be one of the biggest winners of the coming AI applications boom. Think back to the internet. Amazon, YouTube, Facebook and Netflix didn't build the fiber, routers and servers. They built great businesses on top of that infrastructure. AI is heading into the same phase. Palantir $PLTR is a working example. The business is booming, and the stock is up more than 1,000% since early 2024. Apple's edge is distribution. For more than 145 million Americans and over 1 billion people globally, Apple devices are the main gateway to the internet, and increasingly to AI. As AI agents get more capable, people will spend on agentic apps that handle complex tasks and manage daily life. iPhones, iPads and Macs become the interface for all of it. Apple doesn't need the smartest AI model to win. It already owns one of the most valuable distribution networks ever built. TradeSmith's Quantum Score shows a Technical Score of 82 on $AAPL, in line with the breakout. Does $AAPL win the AI applications race without building the best model?

59% of S&P 500 stocks are in bear markets. The index sits only about 2.5% below its record close. That is a narrow market. Reports put about 10 companies behind 70% of the index's gains since March. But look under the hood this week. The S&P 500 fell about 0.5% and the Nasdaq 0.7%, while the Dow gained 0.4% and the Russell 2000 rose 2.0%. Money is rotating, not running. Wednesday at 2pm ET, the Fed announces its rate decision. Futures put about 91% odds on a hold at 3.75% to 4.00%, with roughly 9% odds of a hike. After the close, Microsoft and Alphabet report. Thursday brings Amazon, third-quarter GDP and the September core PCE inflation print. Friday is the employment cost index. The backdrop is tense: Brent near $117, a 10-year yield near 5%, and consumer sentiment at 48.0 with one-year inflation expectations at 4.7%. A narrow market can broaden or break. This week picks a direction. Which report matters most to you: the Fed, Microsoft, Alphabet or Amazon?

9 healthcare stocks hit new one-year highs last week, from Exelixis $EXEL to Waters $WAT to Halozyme $HALO. The full list: $WAT, $MRNA, $EXEL, $HALO, $AVTR, $HTFL, $AMN, Agilent $A and West Pharmaceutical $WST. Look at the spread. Lab instruments, mRNA vaccines, cancer drugs, drug delivery, AI cardiac imaging, healthcare staffing and pharma packaging. When this many different business models break out together, it points to a broad tailwind, not a single hot product. We've been bullish on what we call Boomer healthcare for more than three years. Healthcare has dominated the new-highs list over the past year. The demographic math is hard to argue with. More than 10,000 Americans reach retirement age every day. The U.S. population aged 80 and older is projected to double, from 14.7 million in 2025 to 29.4 million by 2045. Technology is adding fuel to that demand. Genomic sequencing, AI analytics, better imaging and preventive treatments keep creating new tests, tools and therapies. The data backs the move. TradeSmith's Quantum Score on $EXEL sits at 89.7, with a Technical Score of 94.1. An aging population that spends more on care, combined with faster medical innovation, adds up to a long runway. This story has plenty of chapters left. Which of these nine would you own for the next five years?

If the income statement is a video, the balance sheet is a photograph. It freezes one moment and lists what the company owns, what it owes, and what is left over for shareholders. Assets on one side, liabilities and equity on the other, and the two sides always balance. It tells you nothing about how profitable the year was. It tells you how sturdy the company is right now.

$NBIS closed Friday at $158.74. Northland's Street-high target is $410, roughly 2.6 times that price. That gap is not about this year. It is about the run rate. Nebius is targeting $7 billion to $9 billion of annualized revenue, and it is pricing short-duration capacity at $40 million to $50 million per megawatt. Now look at the other side. The stock sits about 47% below its 52-week high of $299.86, yet it is still up about 90% this year. Even the consensus target of $283.60 implies about 78% upside, and 14 of 21 analysts rate it a Buy. The Street is not debating demand. It is debating how fast Nebius can turn power and GPUs into billed revenue. The third-quarter report is the next proof point. If the run rate climbs toward that $7 billion mark, this price will look very different in hindsight. If it stalls, the targets come down. Is $410 a stretch or a roadmap?

PhillipCapital just raised its $SPCX target to $250 from $75 and upgraded SpaceX to Buy. That lands right on the Street average: $250 across 35 analysts. The average target sits about 70% above Friday's $147.49 close. The new piece of the story is wireless. Bloomberg reported SpaceX is in talks for at least 80,000 U.S. cell sites, including Crown Castle $CCI, to build a fourth nationwide carrier. The market priced it in one session: AT&T fell 8%, T-Mobile fell 7.7%, and Crown Castle jumped 9%. The cost will not be small. A nationwide network could run more than $80 billion, on top of $35 billion to $40 billion of expected fourth-quarter capex. Supply is the near-term test. Up to 328.4 million more shares become eligible to trade Monday. The stock just closed a week that included a 1.3 billion share unlock with a gain on Friday. Does SpaceX as a phone carrier change your math on this stock?

6 U.S. hotel and resort REITs hit one-year highs this week: $PK, $RHP, $SHO, $APLE, $DRH and $CLDT. That's not a random list. It's one of the most economically sensitive corners of the market. Hotel owners thrive when consumers have money to travel and businesses are spending on conferences, events and meetings. When the economy wobbles, these are usually among the first stocks to crack. Instead, they're breaking out. Park Hotels & Resorts $PK owns upscale and luxury hotels, mostly Hilton brands. Ryman Hospitality $RHP runs Gaylord convention resorts and Nashville properties tied to the Grand Ole Opry. Sunstone $SHO owns luxury and upper-upscale hotels in major cities and resort markets. Apple Hospitality $APLE, DiamondRock $DRH and Chatham Lodging $CLDT round out the group. The trend behind the move looks solid. TradeSmith's Technical Score on $PK sits at 88.2. This lines up with what we've seen elsewhere. Visa $V, Mastercard $MA, Williams-Sonoma $WSM, Marriott $MAR and Hilton $HLT have all pointed in the same direction. Headlines can be loud. The price action in consumer-facing stocks is louder. Taken together, the signals say U.S. consumer spending and overall economic health are trending up, and the positives outweigh the negatives. When travel and convention stocks are making new highs, it pays to listen to what they're saying about the economy. Are you positioned for a stronger consumer or still bracing for a slowdown?

A company reports three financial statements. Learn what each one is for, and most of the jargon dissolves. The income statement covers a stretch of time, a quarter or a year. Sales at the top, costs taken out in layers, profit at the bottom. It answers one question: did the business make money during this period? It is a story with a beginning and an end. It is not a picture of what the company owns.

Yesterday, Apple $AAPL rose when the tech sector got clobbered. Know why? It's because they're the greatest AI company out there. I've been saying this for 2 years. They're not pioneers in AI. But, they spend pretty much no CapEx on AI and ride the $700b others are spending. They bring AI to life on their device.

$MSFT rose 24.9% in the ten sessions after July's AI selloff trigger. It reports again on Oct 28, five days from now. That is the test July handed us. The selloff did not end on its own. It ended when Microsoft and Amazon posted cloud growth and earnings power alongside their capex. Here is next week's calendar. Microsoft and Alphabet $GOOGL report Oct 28, and Amazon $AMZN reports Oct 29. Apple $AAPL follows on Nov 2, $AMD on Nov 3, and $NVDA is expected in mid-November. The Fed also meets next week. What the market wants to hear is specific. Azure growth guided around 45% in constant currency, up from 43% last quarter. Google Cloud consensus sits near 89% growth, with BofA at 93%. AWS grew 37% last quarter, its fastest in 18 quarters. Capex is the risk on the other side. Alphabet's 2026 spend is tracking around $200B, and BofA has floated $300B for 2027. In July a $15B raise, paired with negative free cash flow, cost $GOOGL 7.1% in a day even with Cloud growing 82%. Microsoft is the name with the cleanest setup. Its Quantum Score on TradeSmith sits at 93.7 with a Technical Score of 95.4. It has also held TradeSmith's Health Green zone since the July reversal. Going into a print, that is the profile you want. The July sequence was simple: beats sold for a week, then two blowouts flipped the tape. If next week brings cloud acceleration, the pattern repeats. If it brings capex without the growth to justify it, July has no map for that outcome. Which print matters most to you next week, $MSFT, $GOOGL, or $AMZN?

$18.6 billion flowed into robotics and physical AI startups in Q2 2026, a record. Yet the robotics ETF $ROBO sits right where it was in April. That gap between stock prices and real-world progress is the setup we're watching. Over the past six months, many of the big robotics winners from mid-2025 to mid-2026 have been digesting large gains. Precision component makers like Cognex $CGNX, Ouster $OUST, Allient $ALNT and Vishay Precision $VPG all had big runs. But the adoption data keeps climbing. North American companies ordered nearly 18,000 robots worth about $1.2 billion in the first half of 2026, with spending up 7% year over year. The company results tell the same story. $CGNX grew Q2 revenue 17% to a record $291 million. Intuitive Surgical $ISRG grew revenue 19% to $2.89 billion and placed 468 da Vinci systems, up from 395 a year earlier. Tesla $TSLA now offers driverless rides in six U.S. cities. Walmart $WMT has passed 1 million drone deliveries, averaging 23 minutes each. The private money is following the parts. PitchBook says startup funding momentum is shifting toward actuators and motion systems, the components every robot needs. That's why we like the picks-and-shovels side of this trend: Nabtesco, Harmonic Drive Systems, $CGNX, $OUST and RBC Bearings $RBC. Stock prices can stall for months. The investment and the technology behind robotics have not stalled at all. Which robotics name would you buy on the pause?

JPMorgan just raised its $SPCX target to $500 from $240. Yesterday, up to 1.31 billion SpaceX shares become eligible to trade as the first lock-up tranche expires. Both numbers matter. The bull side: SpaceX just posted its first profitable quarter as a public company, earning $4.4 billion on revenue of about $14.58 billion, up 161%. Cantor raised its target to $345 and Barclays to $300. The supply side: another 328.4 million shares unlock Oct 24, and 797.6 million more on Dec 8, per published lock-up schedules. Those are maximum eligible shares, not shares that must be sold. The stock closed Wednesday at $159.31, up 8%, short of the $166 level traders were watching. Strong numbers and new supply can hit the same week. Price finds the balance between them. Do you add $SPCX into the unlock or wait for it to clear?